新辅助化疗对卵巢癌肿瘤细胞减灭术手术结局的影响  

Effect of neoadjuvant chemotherapy on the surgical outcomes of interval debulking surgery for advanced ovarian cancer

作　　者：朱连成[1] 林蓓[1] ZHU Lian-cheng;LIN Bei(Department of Gynecology and Obstetrics,Shengjing Hospital of China Medical University,Shenyang 110004,China)

机构地区：[1]中国医科大学附属盛京医院妇产科,辽宁沈阳110004

出　　处：《中国实用妇科与产科杂志》2023年第7期706-711,共6页Chinese Journal of Practical Gynecology and Obstetrics

基　　金：辽宁省科学技术计划(2022JH2/20200047);沈阳市科学技术计划(22-315-6-16);北京康华中西医发展基金会妇科肿瘤专项研究基金(KH-2021-LLZX-010)。

摘　　要：对于晚期卵巢癌患者实施新辅助化疗(neoadjuvant chemotherapy,NACT)联合间歇性肿瘤细胞减瘤术(interval debulking surgery,IDS)有助于达到满意的肿瘤细胞减灭术,降低术后病率,但NACT对手术结局的影响需要进一步的研究探讨。对新诊断的晚期卵巢癌患者进行包括病理学、临床指标及影像学等在内的有效评估,选择适合的患者采用NACT-IDS,有益于降低术后并发症,提高手术满意度,增加微创手术的可能性,但术后生存率可能并未获益,化疗药物耐药及肿瘤复发的风险可能提高,这都提示妇科肿瘤医生要审慎选择NACT,必要时多学科协作,以期达到最佳的治疗效果。The combination of neoadjuvant chemotherapy(NACT)with interval debulking surgery(IDS)for advanced ovarian cancer patients can help achieve satisfactory tumor cytoreductive surgery and reduce postoperative disease rates.However,further research is needed to explore the impact of NACT on surgical outcome evaluation.Effective evaluation of newly diagnosed advanced ovarian cancer patients,including pathology,clinical indicators,and imaging and selection of suitable patients to use NACT-IDS are beneficial for reducing postoperative complications,improving surgical satisfaction,and increasing the possibility of minimally invasive surgery.However,postoperative survival may not be benefited,and chemotherapy drug resistance and the risk of tumor recurrence may increase.This suggests that gynecological oncologists should carefully choose NACT.Multi-disciplinary treatment is necessary to achieve the best treatment effect.

关 键 词：晚期卵巢癌 间歇性肿瘤细胞减瘤术 新辅助化疗 手术结局评估 

分 类 号：R737.31[医药卫生—肿瘤]